More than surgery in the news at AUA annual meeting
Trying to name a single theme characterizing the recently convened AUA annual meeting in Orlando is a tough assignment given the meeting's diversity, but one trend is worth noting: A great deal of the news coming out of this year's biggest meeting of urologic surgeons had little do with surgery at all. Perhaps this observation should come as no surprise. The fact that some of the most widely discussed findings focused on drug and "complementary" therapies rather than surgical techniques may well reflect urology's increasing shift away from complex surgery and toward office-based practice. Whether urology is heading toward a formal two-tiered system of office-based urologists and surgical specialists remains to be seen, but some say such a system is already unfolding.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
